Protagonist says FDA approves Takeda’s MIMRYLO for polycythemia vera erythrocytosis

Reuters2026/08/29 00:30

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

FDA cleared Takeda’s MIMRYLO (rusfertide) for erythrocytosis in adults with polycythemia vera.
Protagonist will receive USD 275 million in milestone payments tied to the approval.
Deal includes 14%-29% tiered royalties on worldwide net sales, with up to USD 875 million in additional potential milestones.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protagonist Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202608282030ACCESSWRNAPR_____1214342) on August 29, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

September is typically the worst-performing month for U.S. stocks, with the S&P 500's average monthly return at its lowest point of the year. Currently, option prices are also at their cheapest level of the year—combining these two factors makes the risk-reward ratio of buying downside protection particularly attractive.

智通财经•2026/08/31 22:56